Skip to main content

Table 4 Outcomes, follow-up and changes in tumor sizes after SAE

From: Efficacy and safety of selective renal arterial embolization in renal angiomyolipoma: a prospective single-center study

Variables Data
Mean follow-up ± SD (min–max), months 6.91 ± 3.41 (1.0–12.0)
Maximum diameter of AMLs, cm  
Before SAE, median (min–max) 13.9 (6.60–25.5)
After SAE, median (min–max) 10.7 (4.7–30.0)
Maximum diameter reduction  
Median (min–max), cm 1.8 (− 7.2–7.0)
Median (min–max), (%) 16.0 (− 32.58–59.83)
Volume of AMLs, cc  
Before SAE, median (min–max) 715.91 (134.18–3533.81)
After SAE, median (min–max) 283.89 (37.33–6322.45)
Volume reduction  
Median (min–max), cc 213.1 (− 3266.67–1711.69)
Median (min–max), (%) 48.44 (− 106.9–94.17)
Serum creatinine level, mL/min  
Before SAE, median (min–max) 0.8 (0.5–2.8)
After SAE, median (min–max) 0.7 (0.40–3.1)
Hemoglobin level, g/dL  
Before SAE, mean ± SD 9.84 ± 2.29
After SAE, mean ± SD 10.72 ± 1.44
Leucocytic count (103/uL)  
Before SAE, mean ± SD 10.56 ± 3.43
After SAE, mean ± SD 10.07 ± 3.38
Hospital stay duration, median (min–max) days 6.0 (1.0–20.0)